



anteo diagnostics
limited

Anteo Diagnostics (ASX:ADO)
FY2011 Annual General Meeting
(AGM)

Better Binding - Faster
Dr. Geoff Cumming - CEO
Monday 24 October, 2011

CEO's Address – Dr Geoff Cumming

- A year of significant progress for Anteo
- An experienced and capable Board of Directors now in place
 - Appointments of Ms Sandra Anderson & Mr Mark Bouris
- Highly experienced management and technical team
 - Dr Joe Maeji, Dr Nevin Abernethy, Dr Tina Baumgartner
- Anteo is financially strong – cash on hand (As at 30 June 2011) \$6.85m
 - Well funded to the end of calendar year 2013, excluding any future revenues
- The platform is now in place to realise the value of the Mix&Go™ technology
- We are grateful for the continued support from our shareholders

For personal use only

CEO's Address - Dr Geoff Cumming

FY2011 Highlights

- July 2010 – ADO announces agreed terms with Merck Chimie SAS
- February 2011 – ADO raises \$5.1m from existing shareholders through option conversion
- February 2011 – Bangs Laboratories launches second product using Mix&Go™
- March 2011 – European Patent Office confirms intention to grant the 'Generation of Surface Coating Diversity' patent for Mix&Go™

For personal use only

CEO's Address - Dr. Geoff Cumming

A snapshot of the Mix&Go™ Technology

- ADO has developed Mix&Go™ – a molecular 'glue' that significantly improves pathology tests
- Mix&Go™ is a novel 'glue' - like a two sided velcro
- Mix&Go™ technology results in earlier detection of disease (more treatment options) OR less expensive test manufacture (less antibody used)
- Mix&Go™ is proven and already licensed to two major healthcare companies – Bangs Laboratories and Merck
- Potential to access numerous and large healthcare segments – pathology (IVD), research, point of care diagnostics, immunoprecipitation
- Mix&Go™ has a solid pipeline of opportunity – over 60 global healthcare companies are currently assessing Mix&Go™ in-house for use/licensing

For personal use only

CEO's Address - Dr Geoff Cumming

Anteo's Short Term Value Drivers

In Vitro Diagnostics (IVD) Market

- Global leading IVD companies currently undertaking real time stability testing and associated studies for Mix&Go™
- The IVD market is valued at \$10 billion per annum

Research & Development (R&D)

- Currently 2-3 healthcare R&D companies actively considering Mix&Go™
- Short term revenue opportunities as R&D companies take less time on approval processes
- ADO pushing into new areas of research, including the effective use of microtitre plates
- ADO currently researching our ability to improve the efficacy of multiplexing - multiple tests from a single bead

For personal use only

A strong start to FY2012

- Appointment of highly experienced Non-Executive Chairman
- Recently hired three new Scientists
- Continued growth of pipeline of opportunities
- Anteo is in excellent shape and well positioned for the year ahead

For personal use only

Shareholder Questions

Dr. Geoff Cumming

Chief Executive Officer

Anteo Diagnostics Limited

Tel: +61 2 8823 3110

For personal use only